UCB SA UCBJY
159.59 USD +5.89 (+3.83%)
Nov 4, 2026, 12:25 PM EST
157.74 Day range 159.59
110.55 52-week range 168.76
- YTD
- +14.19%
- 1 year
- +28.24%
- Market cap
- 60.76B
- EPS (ttm)
- 6.60
- P/E ratio
- 24.18
- YTD return
- +14.19%
- 1-year return
- +28.24%
- Volume
- 3.36K
- Avg volume
- 47.78K
- Open
- 158.58
- Previous close
- 153.70
- Day's range
- 157.74 – 159.59
- 52-week range
- 110.55 – 168.76
- Earnings date
- Feb 25, 2027
2Y +62.28 (+64.00%)
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 3.01.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 3.01 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 2.91 | 3.93 | +1.02 | +35.05% |
| Feb 26, 2026 | Dec 31, 2025 | 2.91 | 3.79 | +0.88 | +30.24% |
| Jul 31, 2025 | Jun 30, 2025 | 1.93 | 1.44 | -0.49 | -25.39% |
| Feb 27, 2025 | Dec 31, 2024 | 1.35 | 4.56 | +3.21 | +237.78% |
| Jul 25, 2024 | Jun 30, 2024 | 0.953 | 1.15 | +0.20 | +20.67% |
News
What's Going On with MoonLake Immunotherapeutics Stock on Thursday? 
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript 
UCB (OTCMKTS:UCBJY) Reaches New 1-Year Low – Should You Sell? 
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript 
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript 
UCB (UCBJY) Upgraded to Buy: Here's Why 
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers 
UCB (OTCMKTS:UCBJY) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? 
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript 
UCB SA (OTCMKTS:UCBJY) Short Interest Down 60.4% in July
Your note
Sign in to keep a note on UCBJY — it syncs with the Stock Master app.